

# EUROPEAN CURRICULUM VITAE FORMAT



## PERSONAL INFORMATION

NAME	ALESSIO MUZI
TITLE	MD
ADDRESS	
TELEPHONE	
E-MAIL	
NATIONALITY	ITALIAN
DOB	

## WORK EXPERIENCE

- DATES (FROM – TO) **DECEMBER 2017 - TO DATE**
- NAME AND ADDRESS OF EMPLOYER **UNIVERSITY OF PERUGIA, CLINICA OCULISTICA  
(CHAIR: PROF. CARLO CAGINI, DEPARTMENT OF MEDICINE  
AND SURGERY, SECTION OF OPHTHALMOLOGY, UNIVERSITY  
OF PERUGIA, S.MARIA DELLA MISERICORDIA HOSPITAL,  
PERUGIA, ITALY)  
RESIDENCY IN OPHTHALMOLOGY  
MEDICAL RETINA AND IMAGING UNIT STAFF PHYSICIAN,  
OPHTHALMOLOGIC SURGERY, RETINAL SURGERY, UVEITES  
SERVICE**
- TYPE OF BUSINESS OR SECTOR **FROM 01/11/2016 TO 19/12/2017**
- OCCUPATION OR POSITION HELD **ASUR MARCHE 4  
MEDICAL DIVISION  
RESIDENT IN GENERAL PRACTITIONERY**
- DATES (FROM – TO) **FROM 01/04/2016 TO 27/11/2017**

- NAME AND ADDRESS OF EMPLOYER **ASUR MARCHE 4**
  - TYPE OF BUSINESS OR SECTOR **MEDICAL DIVISION**
  - OCCUPATION OR POSITION HELD **GENERAL PRACTITIONER (SUBSTITUTE)**
- 
- DATES (FROM – TO) **2009-2015**
  - NAME AND TYPE OF ORGANIZATION PROVIDING EDUCATION AND TRAINING **SCHOOL OF MEDICINE AND SURGERY, UNIVERSITY OF POLITECNICA DELLE MARCHE, ANCONA, ITALY**
  - PRINCIPAL SUBJECTS/OCCUPATIONAL SKILLS COVERED **GENERAL MEDICAL TRAINING**
  - TITLE OF QUALIFICATION AWARDED **MEDICAL DOCTOR, WITH THE 110/110 CUM LAUDE UPDATE ON SERPIGINOUS CHOROIDITIS**

- DATES (FROM – TO) **2005 – 2009**
- NAME AND TYPE OF ORGANIZATION PROVIDING EDUCATION AND TRAINING **ITIS MONTANI, FERMO, ITALY**
- PRINCIPAL SUBJECTS/OCCUPATIONAL SKILLS COVERED **STUDENT**
- TITLE OF QUALIFICATION AWARDED **HIGH SCHOOL DEGREE IN CHEMISTRY SPECIALIZATION, WITH THE 100/100**

**PERSONAL SKILLS AND COMPETENCES**

**CLINICAL RESEARCH ACTIVITY MAINLY DEVOTED TO RETINAL IMAGING (FLUORESCEIN ANGIOGRAPHY, INDOCYANINE GREEN ANGIOGRAPHY, OPTICAL COHERENCE TOMOGRAPHY, AUTOFLUORESCENCE) AND RETINAL DISEASES MANAGEMENT. SOME MANUSCRIPTS PUBLISHED IN PEER-REVIEWED MEDICAL JOURNALS.**

**MOTHER TONGUE**

**ITALIAN**

**OTHER LANGUAGES**

- READING SKILLS
- WRITING SKILLS
- VERBAL SKILLS

**ENGLISH****EXCELLENT****GOOD****GOOD****SOCIAL SKILLS AND COMPETENCES**

**RECOGNIZED APTITUDE FOR TEAM LEADING; HE LOVES TO RELATE WITH COLLEAGUES, ENHANCING PERSONAL SKILLS AND COMPETENCES BY MANAGING THE GROUP IN ORDER TO OPTIMIZE A PRODUCTION OF HIGH-QUALITY RESEARCH.**

**ORGANIZATIONAL SKILLS AND COMPETENCES**

**ATTITUDE TO ORGANIZE AND COORDINATE IN AN INTERDISCIPLINARY FIELD BETWEEN DIFFERENT RESEARCH AREAS.**

**DRIVING LICENSE (S)****A1, B****MULTICENTRIC TRIALS AS CO-INVESTIGATOR****1. GR40349: 2019-IN COURSE. CO-INVESTIGATOR**

SPONSOR: ROCHE. "A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, ACTIVE COMPARATOR CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RO6867561 IN PATIENTS WITH DIABETIC MACULAR EDEMA". Trial (YOSEMITE)

**2. GR40306: 2019-IN COURSE. CO-INVESTIGATOR**

SPONSOR: ROCHE. A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, ACTIVE COMPARATOR CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FARICIMAB IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION". Trial (TENAYA)

**3. CRTH258A2303: 2019-IN COURSE. CO-INVESTIGATOR**

SPONSOR: NOVARTIS. STUDIO A 64-WEEK, TWO-ARM, RANDOMIZED, DOUBLE-MASKED, MULTICENTER, PHASE IIIB STUDY ASSESSING THE EFFICACY AND SAFETY OF BROLUCIZUMAB 6 MG COMPARED TO AFLIBERCEPT 2 MG IN A TREAT-TO-CONTROL REGIMEN IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION". TRIAL: TALON.

**4. MR41986: 2021-IN COURSE. CO-INVESTIGATOR**

SPONSOR: ROCHE. Fase IIb MR41986 ALTIMETER: "AN EXPLORATORY, PROSPECTIVE, MULTI CENTER, OPEN-LABEL, SINGLE-ARM, INTERVENTIONAL, PHASE IIB STUDY TO INVESTIGATE AQUEOUS HUMOR AND MULTIMODAL IMAGING BIOMARKERS IN TREATMENT-NAÏVE PATIENTS WITH DIABETIC MACULAR EDEMA TREATED WITH FARICIMAB (RO6867461) - ALTIMETER STUDY"

**5. BP41783: 2021-IN COURSE. CO-INVESTIGATOR**

SPONSOR: ROCHE. Fase IIb BP41783 "A LONGITUDINAL, BIOMARKER STUDY OF ANTI-VEGF, TO EXPLORE THE RELATIONSHIP BETWEEN AQUEOUS HUMOR COMPOSITION AND MULTIMODAL RETINAL IMAGING IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION AND DIABETIC MACULAR EDEMA". TRIAL: LONGITUDE.

**6. BAY 20968: 2021-IN COURSE. CO-INVESTIGATOR**

SPONSOR: BAYER. RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED, PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF HIGH DOSE AFLIBERCEPT IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. TRIAL: PULSAR.

**7. AMGEN 20170542: 2021-IN COURSE. CO-INVESTIGATOR**

SPONSOR: AMGEN INC. A RANDOMIZED, DOUBLE-MASKED, PHASE 3 STUDY OF ABP 938 EFFICACY AND SAFETY COMPARED TO AFLIBERCEPT (EYLEA®) IN SUBJECTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION

**8. EAGLE study - CO-INVESTIGATOR**

"EVIDENCE OF ANTI-VEGF USE IN REAL LIFE EXPERIENCE – A RETROSPECTIVE COHORT STUDY FROM SECONDARY DATA SOURCE IN ITALY CHART REVIEW" – NOVARTIS.

## 9. "LEADER 7" – NTC. CO-INVESTIGATOR

"STUDIO CLINICO INTERNAZIONALE, MULTICENTRICO, RANDOMIZZATO, CON VALUTATORE IN CIECO, A GRUPPI PARALLELI DI CONFRONTO TRA GOCCE OCULARI CONTENENTI LEVOFLOXACINA + DESAMETASONE PER 7 GIORNI SEGUITI DA SOLO DESAMETASONE PER ALTRI 7 GIORNI RISPETTO A TOBRAMICINA + DESAMETASONE PER 14 GIORNI PER LA PREVENZIONE E IL TRATTAMENTO DELL'INFIAMMAZIONE E LA PREVENZIONE DELLE INFEZIONI ASSOCIATE ALL'INTERVENTO CHIRURGICO PER CATARATTA NEGLI ADULTI"

## TUTOR OF MEDICAL THESIS AT THE SCHOOL OF MEDICINE OF UNIVERSITY OF PERUGIA, ITALY

- STUDIO SULLA CAPACITA' PENETRATIVA E DI AZIONE INTRAOCULARE DI FARMACI SOMMINISTRATI PER VIA TOPICA Graduate: Giulia Ragna A.A. 2020/2021

## PUBLICATIONS IN INTERNATIONAL PEER-REVIEWED JOURNALS

- 1) Cagini C, Mariniello M, Messina M, **Muzi A**, Balducci C, Moretti A, Levorato L, Mencacci A. The role of ozonized oil and a combination of tobramycin/dexamethasone eye drops in the treatment of viral conjunctivitis: a randomized clinical trial. *Int Ophthalmol*. 2020 Dec;40(12):3209-3215. doi: 10.1007/s10792-020-01503-4. Epub 2020 Jul 22. PMID: 32696102; PMCID: PMC7669761 .
- 2) Lupidi M, Gujar R, Cerquaglia A, Chhablani J, Fruttini D, **Muzi A**, Corbucci R, Fiore T, Coscas F, Coscas G, Parravano M, Cagini C. OCT-Angiography as a reliable prognostic tool in laser-treated proliferative diabetic retinopathy: The RENOCTA Study. *Eur J Ophthalmol*. 2020 Nov 2:1120672120963451. doi: 10.1177/1120672120963451.
- 3) Fiore T, Messina M, **Muzi A**, Lupidi M, Reibaldi M, Giansanti F, Cagini C. A novel approach for scleral fixation using Carlevalle lens. *Eur J Ophthalmol*. 2021 Jan 30:1120672121991358. doi: 10.1177/1120672121991358.

- 4) Lupidi M, **Muzi A**, Castellucci G, Kalra G, Piccolino FC, Chhablani J, Cagini C. The Choroidal Rupture: Current Concepts and Insights: Current and novel findings on choroidal rupture. *Surv Ophthalmol*. 2021 Feb 2:S0039-6257(21)00026-6. doi: 10.1016/j.survophthal.2021.01.014.
- 5) Iovino C, Peiretti E, Tatti F, Querques G, Borrelli E, Sacconi R, Chhablani J, Agrawal H, Boon CJF, van Dijk EHC, Cennamo G, Lupidi M, **Muzi A**, Di Iorio V, Iglicki M, Smadar L, Loewenstein A, Zur D. Photodynamic therapy as a treatment option for peripapillary pachychoroid syndrome: a pilot study. *Eye (Lond)*. 2021 Apr 6. doi: 10.1038/s41433-021-01515-z. Epub ahead of print. PMID: 33824506.

#### **NATIONAL AND INTERNATIONAL INSTRUCTIONAL COURSES (Participant)**

- EXCELSIOR FUNDUS PHOTOGRAPH READING CENTER - PULSAR STUDY - SD OCT 22-09-2020
- EXCELSIOR FUNDUS PHOTOGRAPH READING CENTER - PULSAR STUDY— FLUORESCHEIN ANGIOGRAPHY 16-09-2020
- EXCELSIOR FUNDUS PHOTOGRAPH READING CENTER - PULSAR STUDY— FUNDUS PHOTOGRAPHY 15-09-2020
- DARC CERTIFICATION FOR — AMGEN STUDY — 2-FIELD FFA 10-09-2020
- DARC CERTIFICATION FOR — AMGEN STUDY — 2-FIELD DIGITAL COLOR 09-09-2020
- DARC CERTIFICATION FOR — AMGEN STUDY — SD OCT HEIDELBERG 27-08-2020
- EVALUATION AND CERTIFICATION OF VISUAL ACUITY EXAMINER ROOM. 03 LUGLIO 2020
- ESASO ACCADEMY 05/06/2020
- OCT LIVE COURSE HEIDELBERG ACCADEMY PERUGIA, 12/02/2020
- CLINICAL EDGE: VAE AND SC BCVA TRAINING PER TRIALS CLINICO “YOSEMITE” 22 NOVEMBRE 2019
- ETDRS BEST-CORRECTED VISUAL ACUITY CERTIFICATION FOR “TENAYA” 1 MAGGIO 2019
- ALL EYES ON RETINA VENEZIA 29-30 MARZO 2019
- CORSO OCT E OCT-A HEIDELBERG, ROMA 22-23 MARZO 2019
- CLINICAL EDGE: ETDRS BEST-CORRECT VISUAL ACUITY CERTIFICATION FOR “YOSEMITE” 13 FEBBRAIO 2019
- INVESTIGATOR SITE PERSONNEL ICH GP TRAINING CERTIFICATE. ROCHE 04 FEBBRAIO 2019
- CORSO HEIDELBERG ACCADEMY— IMAGING LIVE SESSION PERUGIA 27 SETTEMBRE 2018

#### **SURGICAL ACTIVITY**

Performed surgical procedures at the “S.Maria della Misericordia Hospital” (Azienda Ospedaliera di Perugia, Perugia, Italy from 18<sup>th</sup> June 2018 – to date (data taken from the electronical medical records **ORMAWEB** as **first/principal**

**operator):**

- 36 cataract surgeries
- 2 cryopexies
- 2 cross linking
- 562 intravitreal injections

Il sottoscritto MUZI ALESSIO dichiara che tutti i fatti riportati nel presente curriculum corrispondono a verità ai sensi e per gli effetti degli artt. 46 e 47 del D.P.R. 445/2000.

Il sottoscritto dichiara di essere a conoscenza delle sanzioni penali cui incorre in caso di dichiarazione mendace o contenente dati non più rispondenti a verità, come previsto dall'art. 76 del D.P.R. 28.12.2000, n. 445.

Il sottoscritto dichiara di essere a conoscenza dell'art. 75 del D.P.R. 28.12.2000, n. 445, relativo alla decadenza dai benefici eventualmente conseguenti al provvedimento emanato, qualora l'Amministrazione, a seguito di controllo, riscontri la non veridicità del contenuto della suddetta dichiarazione.

Si allega a tale scopo copia del documento di identità in corso di validità.

Autorizzo il trattamento dei miei dati personali, ai sensi del D.lgs. 196 del 30 giugno 2003 e della sez. 13 GDPR 679/16 – "European general data protection regulation".

**08<sup>th</sup> MAY 2021**

**SIGNATURE**